



## GENERAL PROGRAM

Day	Morning		Afternoon		Evening	
18 <sup>th</sup>	Arriving to Havana, Transfer Havana Airport to "Havana Hotel, Cuba				Free	
19 <sup>th</sup>	8:30 am- Transfer to Workshop Venue		Arriving to "Melia Peninsula Varadero Hotel"		D I I N N E R	
			Registration			Free
			Opening Ceremony			
			KNA 1			
20 <sup>th</sup>	KNA 2-5	<u>Symposium I</u> Basic Topics	L U N C H	<u>Symposium II</u> Diagnostic and Clinical aspects of meningitis diseases/ Poster and Rum testing	Free	
21 <sup>th</sup>	KNA 6	<u>Symposium III</u> Meningococcal Vaccines		KNA 7	<u>Symposium IV</u> Gonococcal vaccine	Free
22 <sup>th</sup>	<u>Round Table</u> 25 years of the Proteoliposome as Human Cuban Vaccine			<u>Symposium V</u> <i>Streptococcus suis</i> : disease and future challenges		Free
23 <sup>th</sup>	KNA 8	<u>Symposium VI</u> Pneumococcal Meningitis and Vaccines		KNA 9	<u>Symposium VII</u> Correlates of Protection	20:30. GYO* Show
				Closing Ceremony		
24 <sup>th</sup>	Bilateral Meetings			Check out and Return to Havana		Free



## Program

Day	Time	Activity
19th	08:30	Transfer to workshop Venue from Havana Hotels
	15:00	Arrive and Registration
	18:00	Opening Ceremony
	18:30	<b>KNA 1: Carbohydrates and T cells: A sweet twosome. Kasper DL, USA</b>
	19:30	Welcome Dinner

### Time for Presentations

**Keynote address (KNA) = 35 min + 10 min for questions**

**Oral Presentation = 25 min + 5 min for questions**

**Short Oral Presentation (SOP) = 10 min + 5 min for questions**

Day	Time	Activity
20th	<b>Symposium I: Basic Topics</b>	
	<b>Chairs: S Meri (Finland) and LM Wetzler (USA)</b>	
	09:00-09:35	<b>KNA 2:</b> Could Adjuvants overcome the Thymus-independent of Polysaccharides? <b>B Romeu, Cuba</b>
	09:45-10:20	<b>KNA 3:</b> Complement activating pattern recognition molecules (PRMs) of the innate immune defence and their possible role in Neisserial infections. <b>J Chr Jensenius, Denmark</b>
	10:30-11:05	<b>KNA 4:</b> Opportunities and risks of using complement regulator binding proteins as vaccines. <b>S Meri, Finland</b>
	11:15-11:50	<b>KNA 5:</b> Mechanism of the Immune Stimulating Activity of the Neisserial Major Outer Membrane Protein PorB: Role of Antigen Presenting Cells and Systems Immunobiology Analysis. <b>LM Wetzler, USA</b>
12:00-12:25	The Meningitis Research Foundation Meningococcal Genome Library. <b>J Lucidarme, UK</b>	

12:30-14:30

Lunch

Day	Time	Activity
20th	<b>Symposium II: Diagnostic and Clinical aspects for Meningitis Diseases</b>	
	<b>Chairs: E Kaczmarski (UK) and J Diez-Dominguez (Spain)</b>	
	14:30-14:55	Rapid diagnostics for meningitis Diseases. <b>UK</b>
	15:00-15:25	Bacterial meningitis in Cuba. Clinical and epidemiological situation. <b>J Pérez, Cuba</b>
	15:30-15:55	Meningococcal disease. Beyond the figures. <b>J Diez-Domingo, Spain</b>
16:00-16:25	Lab safe working with meningococci. <b>E Kaczmarski, UK</b>	

16:35-18:35

Poster Session

Symposium III: Meningococcal Vaccines	
<b>Chairs: J Holst (Norway) and G Enwere (France)</b>	
21th	<b>09:00-09:35</b> <b>KNA 6:</b> A long and winding road: towards a vaccine with broad strain-coverage against meningococcal serogroup B disease. <b>J Holst, Norway</b>
	<b>09:45-10:10</b> Early development of MenBioVax vaccine with potential for universal protection against <i>Neisseria meningitidis</i> . <b>S Clarke, UK</b>
	<b>10:15-10:40</b> A new approach to prevention and treatment of meningococcal disease. <b>C Blackwell, Australia</b>
	<b>10:45-11:10</b> Subcapsular meningococcal vaccine antigens in the common childhood commensal, <i>Neisseria lactamica</i> . <b>J Lucidarme, UK</b>
	<b>11:15-11:25</b> <b>SOP 1:</b> Conjugated vaccine candidate against <i>Neisseria meningitidis</i> . <b>R Acevedo, Cuba</b>
	<b>11:30-11:55</b> Progress and perspectives of MenAfriVac, a meningococcal A conjugate vaccine for the African meningitis belt. <b>G Enwere, France</b>
	<b>12:00-12:25</b> A trivalent outer membrane vesicle (OMV) vaccine against meningococcal disease for Africa. <b>E Rosenqvist, Norway</b>
	<b>12:30-12:40</b> <b>SOP 2:</b> An approach to tetravalent vaccine production from polysaccharide of <i>N. meningitidis</i> serogroups ACYW <sub>135</sub> , to Muslim market. <b>D González, Cuba</b>
	<b>12:45-12:55</b> <b>SOP 3:</b> New vaccines strategies against <i>Neisseria meningitidis</i> serogroup X. <b>C Zayas, Cuba</b>

13:00-14:30

**Lunch**

Symposium IV: Gonococcal vaccine	
<b>Chairs: P. Rice (USA) and L. Velásquez (Chile)</b>	
21th	<b>14:30-15:15</b> <b>KNA 7:</b> Saccharide antibody protection against <i>Neisseria gonorrhoeae</i> infections in the experimental mouse model can reversed by anti. Rmp antibody. <b>P Rice, USA</b>
	<b>15:25-15:50</b> Role of glycocalyx and matrix extracellular proteins in the pathogenesis of <i>Neisseria gonorrhoeae</i> on fallopian tube cells. <b>L Velásquez, Chile</b>
	<b>15:55-16:20</b> Surfactant vesicles as a surrogate for whole cell vaccination allow for inclusion of lipooligosaccharide in vaccine preparations. <b>D Stein, USA</b>
	<b>16:25-16:50</b> RNA-seq Analysis of Vaginal Lavage Samples from Female Patients Identifies a Repertoire of Putative Gonococcal Vaccine Targets. <b>C Genco, USA.</b>

<b>Round Table 25 years of the Proteoliposome as Human Cuban Vaccine</b>	
<b>Chairs: D Cardoso (Cuba) and E Rosenqvist (Norway)</b>	
<b>22th</b>	<b>09:00-09:40</b> VA-MENGOC-BC <sup>®</sup> : Landmarks of a Vaccine. <b>C Campa, G Sierra, Cuba</b>
	<b>09:40-10:00</b> Controversies Regarding Clinical Use of VA-MENGOC-BC <sup>®</sup> . <b>R Ochoa, Cuba</b>
	<b>10:00-10:20</b> VA-MENGOC-BC <sup>®</sup> : 25 years of security and efficacy preclinical trials. <b>JF Infante, Cuba</b>
	<b>10:20-10:40</b> Post-license surveillance of VA-MENGOC-BC <sup>®</sup> . <b>I. Cuevas, Cuba</b>
	<b>10:40-11:00</b> Technological platform for VA-MENGOC-BC <sup>®</sup> production. <b>R Barberá, Cuba</b>
	<b>11:00-11:20</b> Commercial experiences of VA-MENGOC-BC <sup>®</sup> . <b>E Caro, Cuba</b>
	<b>11:20-11:40</b> Proteoliposome as the core of VA-MENGOC-BC <sup>®</sup> and adjuvant platform. <b>O Pérez, Cuba</b>
	<b>11:40-</b> Opinions of other Finlay's Members and Colleagues

**12:30-14:30**

**Lunch**

<b>Symposium V: <i>Streptococcus suis</i>: disease and future challenges</b>	
<b>Chairs: V Verez (Cuba) and M Gottschalk (Canada)</b>	
<b>22th</b>	<b>14:30-14:55</b> Overview of <i>Streptococcus suis</i> epidemiology of the disease and vaccine update <b>M Gottschalk, Canada</b>
	<b>15:00-15:25</b> Molecular typing of <i>Streptococcus suis</i> from pigs in Cuba. <b>I Espinosa, Cuba</b>
	<b>15:30-15:55</b> The immune response against <i>Streptococcus suis</i> : sepsis and toxic shock. <b>M Segura, Canada</b>
	<b>16:00-16:25</b> The pathogenesis of the <i>Streptococcus suis</i> meningitis. <b>M Gottschalk, Canada</b>
	<b>16:30-16:55</b> New chemical methods for conjugate vaccines: is there an avenue for <i>Streptococcus suis</i> ? <b>R Roy, Canada</b>
	<b>17:00-17:25</b> Learning from <i>Streptococcus pneumoniae</i> conjugate vaccine for <i>S. suis</i> meningitis. <b>Y Valdés, Cuba</b>



Symposium VI: Pneumococcal meningitis and Vaccines		
Chairs: W Hausdorff (USA) and V Verez (Cuba)		
23th	09:00-09:35	<b>KNA 8:</b> Epidemiology of pneumococcal meningitis, serotypes responsible, and the need and prospect for protein vaccines. <b>W Hausdorff, USA</b>
	09:45-10:10	Impact of pneumococcal conjugate vaccines on pneumococcal meningitis in Latin America. <b>JL Di Fabio, PAHO</b>
	10:15-10:40	UK experience with pneumococcal meningitis and PCV. <b>R Borrow, UK</b>
	10:45-11:10	Immunological considerations and lessons in comparisons of bacterial meningitis vaccines against Hib, meningococcus and pneumococcus. <b>D Goldblatt, UK</b>
	11:15-11:40	<i>Streptococcus pneumoniae</i> conjugate vaccine development in Cuba. <b>V Verez, Cuba</b>

12:30-14:30

Lunch

Symposium VII: Correlates of protection for <i>Neisseria meningitidis</i> and <i>Streptococcus pneumoniae</i>		
Chairs: R. Borrow (UK) and D. Medini (Italy)		
23th	14:30-15:05	<b>KNA 9:</b> Issues with correlates of protection for quadrivalent meningococcal ACWY glycoconjugate vaccines. <b>R Borrow, UK.</b>
	15:15-15:40	The preparation and use of IgG-depleted complement in meningococcal vaccine assessment. <b>E Kuisma, UK.</b>
	15:45-16:10	Evaluating the efficacy of fHBP containing vaccines using hSBA, the surrogate of protection. <b>L York, USA</b>
	16:15-16:40	Serum Bactericidal Antibody against capsular group B meningococcal isolates responsible for invasive disease shows that MATS is a conservative predictor of strain coverage by the 4CMenB vaccine. <b>D Medini, Italy.</b>
	16:45-17:10	Carriage as an endpoint for licensing vaccines: lessons from PneumoCarr. <b>D Goldblatt, UK.</b>
	17:15-17:30	<b>SOP 4:</b> Use of serum bactericidal antibody as an evaluation method for immunogenicity of meningococcal vaccines serogroups A, B, C, X, and W <sub>135</sub> . <b>L García, Cuba</b>

17:30

Closing Ceremony

20:30

GYO\* Show



**IV Neisseria Vaccines 2013**  
**I Workshop on Meningitis and Septicaemia**  
**International Congress on Meningeal Disease Vaccines**  
 Varadero, Cuba, May 19-24, 2013

<b>24<sup>th</sup></b>	<b>09:00-11:35</b>	<b>Bilateral Meetings and Free interchange between Delegates</b>
	<b>12:00-13:00</b>	<b>Lunch</b>
	<b>14:00</b>	<b>Return to Havana</b>

<b>20<sup>th</sup></b>	<b>16:25-18:25</b>	<b>Poster Session</b>
------------------------	--------------------	-----------------------

<b>24<sup>th</sup></b>	<b>Conferences in Havana for Pediatrician, Immunologists and Microbiologist “William Soler” Hospital</b>	
	<b>11:00-</b>	<b>Pneumococcal conjugate vaccines: what have we learned and what do we have yet to learn? W Hausdorff, Belgium</b>
		<b>Understanding Responses to Polysaccharide and Conjugate Vaccines in infants and adults. D Goldblatt, UK</b>

No	Titles y Authors
1	Four monoclonal antibodies against capsular polysaccharides of <i>Neisseria meningitidis</i> serogroups A, C, Y and W <sub>135</sub> : its application in identity tests. <b>N Amín, Cuba</b>
2	Development of sandwich ELISAs for detection and quantification of capsular polysaccharides of <i>Neisseria meningitidis</i> serogroups A, C, W <sub>135</sub> and Y. <b>F Reyes, Cuba</b>
3	Latex particles as potential reagents for diagnostic of meningococcal disease <b>M Cuello, Cuba</b>
4	Evaluation of a rapid test for the detection of <i>Neisseria meningitidis</i> serogroup B in human serum and whole blood using a novel affinity biosensor. <b>X Bai, UK</b>
5	SDS-PAGE and densitometric analysis to determine the concentration of Lipopolysaccharide from <i>Neisseria meningitidis</i> serogrupos A, W <sub>135</sub> , Y and X. <b>M Cuello, Cuba</b>
6	Identification of antigenic composition of outer membrane vesicles from <i>Neisseria meningitidis</i> serogroup X. <b>Y Rodríguez, Cuba</b>
7	New methodology western blot technique in identity assay. Optimization and Validation. <b>R Diéguez, Cuba</b>
8	Characterization of dry polysaccharides from <i>Neisseria meningitidis</i> serogroups A, C, Y and W <sub>135</sub> to be used as internal controls. <b>LD Díaz, Cuba</b>
9	Comparative results of the individual polysaccharides A, C, Y, and W <sub>135</sub> and the tetravalent vaccine ACWY by using pyrogen test. <b>JF Núñez, Cuba</b>
10	Predicting serum bactericidal responses: sensitivity and specificity of a flow-cytometric complement deposition assay. <b>L Allen, UK</b>
11	Bridging of two serum bactericidal antibody assays using rabbit complement performed at the Health Protection Agency and at GlaxoSmithKline Biologicals. <b>X Bai, UK</b>
12	A model system for assessment of opsonisation of meningococci and commensal species. <b>CC Blackwell, Australia.</b>
13	Establishment of Quality Assurance System for the production of polysaccharides from <i>Neisseria meningitidis</i> serogroups A, C, Y and W <sub>135</sub> under HALAL requirements. <b>R Martínez, Cuba</b>
14	Development and Validation the analytical methods in Polysaccharide W <sub>135</sub> of Meningococcal Vaccines. <b>I Delgado, Cuba</b>
15	Development and Validation of method for quantification multivalent polysaccharides vaccines by Capillary Zone Electrophoresis. <b>Y Merchán, Cuba</b>
16	Validation of a RI-HPLC ethanol determination method. Characterization of these impurity in VA-MENGOC BC <sup>®</sup> vaccine. <b>M Cuevas, Cuba</b>



17	Validation of the sterilization equipments for saturated steam (autoclaves) used in the meningococcal vaccines production at Finlay Institute. <b>M Hernández, Cuba</b>
18	Concurrent validation of the process for obtaining dry polysaccharide from <i>Neisseria meningitidis</i> serogroup C. <b>JV Bayolo, Cuba</b>
19	Stability studies of a <i>Neisseria Meningitidis</i> serogroups A and W <sub>135</sub> vaccine based on outer membrane vesicle. <b>A Mandiarote, Cuba</b>
20	New process evaluation at large scale to obtain capsular polysaccharide purified from <i>Neisseria meningitidis</i> serogroup W <sub>135</sub> . <b>S Lozada, Cuba</b>
21	Stability studies for Polysaccharides and final lots of a trivalent <i>Neisseria meningitidis</i> serogroups A, C, and W <sub>135</sub> vaccine. <b>E Pérez, Cuba</b>
22	Clinical Trials Audit to the <i>Neisseria meningitidis</i> A, C, and W <sub>135</sub> Polysaccharide vaccine from Finlay Institute. <b>B Simón, Cuba</b>
23	Purification of lipopolysaccharides from <i>Neisseria meningitidis</i> for use as reference material for its quantification in vaccines. <b>RA Cabrera, Cuba</b>
24	Production of free porcine components <i>Neisseria meningitidis</i> Reference Seed Lots. <b>CA del Puerto, Cuba</b>
25	Stability of working seed lot of <i>Neisseria meningitidis</i> serogroup X grown in culture media of non-animal origin and preserved by freezing. <b>M Hernández, Cuba</b>
26	<i>Neisseria meningitidis</i> serogroup X: analytical challenges and alternatives for evaluation polysaccharide content by quantitative nuclear magnetic resonance. <b>R Garrido, Cuba</b>
27	Conjugation of Capsular Polysaccharides from <i>Neisseria meningitidis</i> Serogroups X to Tetanus Toxoid. <b>M González, Cuba</b>
28	Vaccine potential of outer membrane vesicles from <i>Neisseria meningitidis</i> serogroup X. <b>C Zayas, Cuba</b>
29	Preparation and <b>characterization</b> of conjugates from <i>Streptococcus pneumoniae</i> serotypes 7F, 9V and 19A to different carrier proteins. <b>D Mariño, Cuba</b>
30	Adjuvation of conjugates from <i>Streptococcus pneumoniae</i> serotype 1 and 14 to tetanus toxoid in Aluminium. <b>Y Serrano, Cuba</b>
31	Group B meningococcal vaccine candidacy of haemoglobin receptors based on distribution and phase variable status. <b>J Lucidarme, UK</b>
32	Comparison of cytokine gene polymorphisms among Greek patients with invasive meningococcal disease or viral meningitis. <b>CC Blackwell, Australia.</b>
33	A novel factor H-Fc chimeric immunotherapeutic molecule against <i>Neisseria gonorrhoeae</i> . <b>P Rice, USA</b>
34	Antimicrobial resistance patterns in Cuban gonococcal strains. <b>O Feliciano, Cuba</b>
35	The utility of PCR in diagnostic of unspecified and treated bacterial meningitis in Cuba. <b>O Feliciano, Cuba</b>

<b>36</b>	Epidemiological markers and antimicrobial susceptibility of invasive strains. Cuba, 2002-2011. <b>E Suárez, Cuba</b>
<b>37</b>	Intrathecal synthesis of complement system proteins in patients with eosinophilic meningitis due to <i>Angiostrongylus cantonensis</i> . <b>B Padilla, Cuba</b>
<b>38</b>	MASP2 Intrathecal synthesis in eosinophilic meningitis due to <i>Angiostrongylus cantonensis</i> . <b>A Arias, Cuba</b>
<b>39</b>	MASP2: Dynamics and Intrathecal synthesis. <b>AJ Dorta, Cuba</b>
<b>40</b>	Immunological response identified in cerebrospinal fluid in patients with neurodegenerative diseases. <b>I Zerr, Germany</b>